NCT05788328View on ClinicalTrials.gov

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

September 11, 2023

Study Completion Date

September 11, 2023

Conditions
Healthy
Interventions
DRUG

Dabigatran etexilate (DE)

Dabigatran etexilate (DE) as oral capsule

DRUG

Rosuvastatin

Rosuvastatin as oral tablet

DRUG

PF-07081532

PF-07081532 as oral tablets

Trial Locations (1)

33143

Qps-Mra, Llc, South Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05788328 - A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants | Biotech Hunter | Biotech Hunter